Literature DB >> 23669338

Effect of cyclosporine on lymphocytic variant hypereosinophilic syndrome.

Rie Tabata1, Chiharu Tabata, Yuki Katashima, Ryoji Yasumizu.   

Abstract

Lymphocytic variant hypereosinophilic syndromes (L-HES) is thought to be caused by the over-production of interleukin (IL)-5 by type 2 helper cells, which leads to reactive eosinophil expansion and activation. Here we demonstrate the effect of cyclosporine in a patient with L-HES. In the present case, the surface markers of cells from resected lymph nodes or peripheral blood were analyzed by flow cytometry. Serum concentrations of IL-4, IL-5, and IL-8 were measured using an enzyme-linked immunosorbent assay. Methyl-prednisolone pulse therapy followed by the administration of 150 mg/day of cyclosporine combined with 15 mg/day of prednisolone ameliorated eosinophilia. However, abnormal CD3-CD4+ T cell clones remained even when the eosinophil count recovered to normal levels. An elevated IL-8 level was observed only when eosinophils increased. On the other hand, serum IL-4 and IL-5 levels were under detectable limits during the course. Cyclosporine was effective in decreasing the eosinophil count without the elimination of abnormal T cell clones in the present case. Cytotoxic agents may be necessary to cure this serious disease. Moreover, target therapy for IL-8 may be a new strategy for L-HES with high IL-8 and low IL-5 concentrations.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23669338     DOI: 10.1016/j.intimp.2013.04.033

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  3 in total

Review 1.  Consultation for Elevated Blood Eosinophils: Clinical Presentations, High Value Diagnostic Tests, and Treatment Options.

Authors:  Paneez Khoury; Bruce S Bochner
Journal:  J Allergy Clin Immunol Pract       Date:  2018 Sep - Oct

Review 2.  Management of hypereosinophilia in tropical settings.

Authors:  Arjun Datt Law; Subhash Chander Varma
Journal:  Med J Armed Forces India       Date:  2014-12-25

3.  Characterization of disease flares and impact of mepolizumab in patients with hypereosinophilic syndrome.

Authors:  Fabrizio Pane; Guillaume Lefevre; Namhee Kwon; Jane H Bentley; Steven W Yancey; Jonathan Steinfeld
Journal:  Front Immunol       Date:  2022-08-26       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.